Your browser doesn't support javascript.
loading
Exposure to secondhand aerosol from electronic cigarettes at homes: A real-life study in four European countries.
Amalia, Beladenta; Fu, Marcela; Tigova, Olena; Ballbè, Montse; Paniello-Castillo, Blanca; Castellano, Yolanda; Vyzikidou, Vergina K; O'Donnell, Rachel; Dobson, Ruaraidh; Lugo, Alessandra; Veronese, Chiara; Pérez-Ortuño, Raúl; Pascual, José A; Cortés, Nuria; Gil, Fernando; Olmedo, Pablo; Soriano, Joan B; Boffi, Roberto; Ruprecht, Ario; Ancochea, Julio; López, Maria J; Gallus, Silvano; Vardavas, Constantine; Semple, Sean; Fernández, Esteve.
Afiliação
  • Amalia B; Tobacco Control Unit, Catalan Institute of Oncology - ICO, WHO Collaborating Centre for Tobacco Control, L'Hospitalet de Llobregat, Barcelona, Spain; Tobacco Control Research Group, Bellvitge Biomedical Research Institute - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; School of Medicine and
  • Fu M; Tobacco Control Unit, Catalan Institute of Oncology - ICO, WHO Collaborating Centre for Tobacco Control, L'Hospitalet de Llobregat, Barcelona, Spain; Tobacco Control Research Group, Bellvitge Biomedical Research Institute - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; School of Medicine and
  • Tigova O; Tobacco Control Unit, Catalan Institute of Oncology - ICO, WHO Collaborating Centre for Tobacco Control, L'Hospitalet de Llobregat, Barcelona, Spain; Tobacco Control Research Group, Bellvitge Biomedical Research Institute - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; School of Medicine and
  • Ballbè M; Tobacco Control Unit, Catalan Institute of Oncology - ICO, WHO Collaborating Centre for Tobacco Control, L'Hospitalet de Llobregat, Barcelona, Spain; Tobacco Control Research Group, Bellvitge Biomedical Research Institute - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; CIBER Respiratory Dise
  • Paniello-Castillo B; Tobacco Control Unit, Catalan Institute of Oncology - ICO, WHO Collaborating Centre for Tobacco Control, L'Hospitalet de Llobregat, Barcelona, Spain; Tobacco Control Research Group, Bellvitge Biomedical Research Institute - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Castellano Y; Tobacco Control Unit, Catalan Institute of Oncology - ICO, WHO Collaborating Centre for Tobacco Control, L'Hospitalet de Llobregat, Barcelona, Spain; Tobacco Control Research Group, Bellvitge Biomedical Research Institute - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; School of Medicine and
  • Vyzikidou VK; Hellenic Cancer Society - George D. Behrakis Research Lab - HCS, Athens, Greece.
  • O'Donnell R; Institute for Social Marketing and Health, University of Stirling, Stirling, Scotland, United Kingdom of Great Britain and Northern Ireland.
  • Dobson R; Institute for Social Marketing and Health, University of Stirling, Stirling, Scotland, United Kingdom of Great Britain and Northern Ireland.
  • Lugo A; Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri - IRCCS, Milan, Italy.
  • Veronese C; IRCCS Istituto Nazionale dei Tumori - INT Foundation, Milan, Italy.
  • Pérez-Ortuño R; Hospital del Mar Medical Research Institute - IMIM, Barcelona, Spain.
  • Pascual JA; Hospital del Mar Medical Research Institute - IMIM, Barcelona, Spain; Department of Experimental and Health Sciences, University Pompeu Fabra - UPF, Barcelona, Spain.
  • Cortés N; Agència de Salut Pública de Barcelona - ASPB, Barcelona, Spain.
  • Gil F; Department of Legal Medicine and Toxicology, School of Medicine, University of Granada - UG, Granada, Spain.
  • Olmedo P; Department of Legal Medicine and Toxicology, School of Medicine, University of Granada - UG, Granada, Spain.
  • Soriano JB; CIBER Respiratory Diseases - CIBERES, Instituto de Salud Carlos III, Madrid, Spain; Respiratory Department, Hospital Universitario La Princesa, Madrid, Spain.
  • Boffi R; IRCCS Istituto Nazionale dei Tumori - INT Foundation, Milan, Italy.
  • Ruprecht A; IRCCS Istituto Nazionale dei Tumori - INT Foundation, Milan, Italy.
  • Ancochea J; CIBER Respiratory Diseases - CIBERES, Instituto de Salud Carlos III, Madrid, Spain; Respiratory Department, Hospital Universitario La Princesa, Madrid, Spain.
  • López MJ; Agència de Salut Pública de Barcelona - ASPB, Barcelona, Spain; CIBER de Epidemiología y Salud Pública - CIBERESP, Madrid, Spain; Institut d'Investigació Biomèdica Sant Pau - IIB St. Pau, Barcelona, Spain.
  • Gallus S; Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri - IRCCS, Milan, Italy.
  • Vardavas C; School of Medicine, University of Crete, Heraklion, Greece; Department of Oral Health Policy and Epidemiology, Harvard School of Dental Medicine, Harvard University, Boston, MA, USA.
  • Semple S; Institute for Social Marketing and Health, University of Stirling, Stirling, Scotland, United Kingdom of Great Britain and Northern Ireland.
  • Fernández E; Tobacco Control Unit, Catalan Institute of Oncology - ICO, WHO Collaborating Centre for Tobacco Control, L'Hospitalet de Llobregat, Barcelona, Spain; Tobacco Control Research Group, Bellvitge Biomedical Research Institute - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; School of Medicine and
Sci Total Environ ; 854: 158668, 2023 Jan 01.
Article em En | MEDLINE | ID: mdl-36099951
ABSTRACT
Electronic cigarette (e-cigarette) use emits potentially hazardous compounds and deteriorates indoor air quality. Home is a place where e-cigarettes may frequently be used amid its increasing prohibition in public places. This study assessed the real-life scenario of bystanders' exposure to secondhand e-cigarette aerosol (SHA) at home. A one-week observational study was conducted within the TackSHS project in four countries (Greece, Italy, Spain, and the United Kingdom) in 2019 including 1) homes of e-cigarette users living together with a non-user/non-smoker; and 2) control homes with no smokers nor e-cigarette users. Indoor airborne nicotine, PM2.5, and PM1.0 concentrations were measured as environmental markers of SHA. Biomarkers, including nicotine and its metabolites, tobacco-specific nitrosamines, propanediol, glycerol, and metals were measured in participants' saliva and urine samples. E-cigarette use characteristics, such as e-cigarette refill liquid's nicotine concentration, e-cigarette type, place of e-cigarette use at home, and frequency of ventilation, were also collected. A total of 29 e-cigarette users' homes and 21 control homes were included. The results showed that the seven-day concentrations of airborne nicotine were quantifiable in 21 (72.4 %) out of 29 e-cigarette users' homes; overall, they were quite low (geometric mean 0.01 µg/m3; 95 % CI 0.01-0.02 µg/m3) and were all below the limit of quantification in control homes. Seven-day concentrations of PM2.5 and PM1.0 in e-cigarette and control homes were similar. Airborne nicotine and PM concentrations did not differ according to different e-cigarette use characteristics. Non-users residing with e-cigarette users had low but significantly higher levels of cotinine, 3'-OH-cotinine and 1,2-propanediol in saliva, and cobalt in urine than non-users living in control homes. In conclusion, e-cigarette use at home created bystanders' exposure to SHA regardless of the e-cigarette use characteristics. Further studies are warranted to assess the implications of SHA exposure for smoke-free policy.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Poluição por Fumaça de Tabaco / Sistemas Eletrônicos de Liberação de Nicotina Tipo de estudo: Observational_studies Limite: Humans Idioma: En Revista: Sci Total Environ Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Poluição por Fumaça de Tabaco / Sistemas Eletrônicos de Liberação de Nicotina Tipo de estudo: Observational_studies Limite: Humans Idioma: En Revista: Sci Total Environ Ano de publicação: 2023 Tipo de documento: Article